---
schema_version: "secwatch.filing_event.v1"
accession: "0001649094-25-000073"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T08:18:56.361888+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte Q1 net loss $140.7M; VAX-24 infant data positive, VAX-31 Phase 3 set for mid-2025

## Summary
- Net loss $140.7M vs $95.0M YoY; cash, equivalents & investments $2.95B at March 31, 2025.
- VAX-24 infant Phase 2 met non-inferiority criteria for 20 of 24 serotypes; robust OPA responses.
- VAX-31 infant Phase 2 advanced to second stage; adult Phase 3 non-inferiority study to start mid-2025.
- New third-generation PCV candidate VAX-XL announced to further expand serotype coverage.
- Dr. Olivier Brandicourt (ex-Sanofi CEO) appointed to Board of Directors.

## SEC filing metadata
- accession: 0001649094-25-000073
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000164909425000073/0001649094-25-000073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000164909425000073/pcvx-20250507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001649094-25-000073
- JSON: https://secwatch.observer/filing/0001649094-25-000073.json
- Plain text: https://secwatch.observer/filing/0001649094-25-000073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.